Nutriband (NASDAQ:NTRB) Stock Price Down 1% – Time to Sell?

Nutriband Inc. (NASDAQ:NTRB)’s stock price traded down 1% during trading on Thursday . The company traded as low as $3.03 and last traded at $3.06. Approximately 11,387 shares traded hands during trading, a decline of 11% from the average daily volume of 12,846 shares. The stock had previously closed at $3.09.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Nutriband from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, June 17th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Reduce”.

Nutriband Trading Down 1.0%

The business has a fifty day moving average of $3.50 and a 200-day moving average of $3.99. The company has a market cap of $37.20 million, a PE ratio of -1.19 and a beta of 1.93.

Nutriband (NASDAQ:NTRB) last released its quarterly earnings data on Thursday, June 11th. The company reported ($0.10) earnings per share for the quarter. The business had revenue of $0.43 million during the quarter. Nutriband had a negative return on equity of 112.64% and a negative net margin of 448.25%.

Institutional Trading of Nutriband

An institutional investor recently raised its position in Nutriband stock. Vanguard Group Inc. boosted its stake in Nutriband Inc. (NASDAQ:NTRB) by 1.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 202,738 shares of the company’s stock after acquiring an additional 3,111 shares during the period. Vanguard Group Inc. owned 1.68% of Nutriband worth $1,429,000 at the end of the most recent reporting period. 19.70% of the stock is owned by institutional investors.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.